News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
131,345 Results
Type
Article (7608)
Company Profile (57)
Press Release (123677)
Multimedia
Podcasts (22)
Webinars (5)
Section
Business (38473)
Career Advice (89)
Deals (5996)
Drug Delivery (10)
Drug Development (23812)
Employer Resources (12)
FDA (3061)
Job Trends (3591)
News (69224)
Policy (4617)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Standard (1)
Academia (328)
Accelerated approval (12)
Adcomms (13)
Allergies (3)
Alliances (11291)
ALS (21)
Alzheimer's disease (162)
Antibody-drug conjugate (ADC) (252)
Approvals (3220)
Artificial intelligence (174)
Autoimmune disease (55)
Automation (5)
Bankruptcy (55)
Best Places to Work (3303)
BIOSECURE Act (1)
Biosimilars (89)
Biotechnology (50)
Bladder cancer (126)
Brain cancer (47)
Breast cancer (488)
Cancer (3515)
Cardiovascular disease (36)
Career advice (82)
Career pathing (5)
CAR-T (126)
CDC (3)
Cell therapy (266)
Cervical cancer (18)
Clinical research (21240)
Collaboration (684)
Company closure (2)
Compensation (215)
Complete response letters (10)
COVID-19 (352)
CRISPR (26)
C-suite (290)
Cystic fibrosis (8)
Data (2253)
Decentralized trials (1)
Denatured (4)
Depression (11)
Diabetes (38)
Diagnostics (1405)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (5)
Drug discovery (98)
Drug pricing (25)
Drug shortages (1)
Duchenne muscular dystrophy (27)
Earnings (13966)
Editorial (12)
Employer branding (2)
Employer resources (13)
Events (24882)
Executive appointments (315)
FDA (3904)
Fibrodysplasia Ossificans Progressiva (3)
Frontotemporal dementia (2)
Funding (328)
Gene editing (44)
Generative AI (17)
Gene therapy (91)
GLP-1 (127)
Government (487)
Guidances (87)
Healthcare (4068)
HIV (8)
Huntington's disease (3)
IgA nephropathy (17)
Immunology and inflammation (70)
Immuno-oncology (60)
Indications (55)
Infectious disease (391)
Inflammatory bowel disease (35)
Inflation Reduction Act (3)
Influenza (15)
Intellectual property (57)
Interviews (12)
IPO (2992)
IRA (8)
Job creations (484)
Job search strategy (70)
JPM (25)
Kidney cancer (17)
Labor market (9)
Layoffs (140)
Leadership (6)
Legal (477)
Liver cancer (48)
Longevity (1)
Lung cancer (522)
Lymphoma (225)
Machine learning (14)
Management (3)
Manufacturing (135)
MASH (6)
Medical device (878)
Medtech (883)
Mergers & acquisitions (3261)
Metabolic disorders (106)
Multiple sclerosis (15)
NASH (1)
Neurodegenerative disease (30)
Neuropsychiatric disorders (9)
Neuroscience (320)
NextGen: Class of 2026 (955)
Non-profit (503)
Now hiring (18)
Obesity (60)
Opinion (38)
Ovarian cancer (132)
Pain (27)
Pancreatic cancer (168)
Parkinson's disease (31)
Partnered (1)
Patents (93)
Patient recruitment (160)
Peanut (2)
People (13498)
Pharmaceutical (12)
Pharmacy benefit managers (3)
Phase 1 (8021)
Phase 2 (8878)
Phase 3 (6845)
Pipeline (1687)
Policy (33)
Postmarket research (472)
Preclinical (2535)
Press Release (2)
Prostate cancer (170)
Psychedelics (4)
Radiopharmaceuticals (187)
Rare diseases (144)
Real estate (753)
Recruiting (5)
Regulatory (4772)
Reports (8)
Research institute (696)
Resumes & cover letters (11)
RNA editing (2)
RSV (10)
Schizophrenia (37)
Series A (65)
Series B (30)
Service/supplier (1)
Sickle cell disease (37)
Special edition (3)
Spinal muscular atrophy (16)
Sponsored (6)
Startups (766)
State (1)
Stomach cancer (12)
Supply chain (12)
Tariffs (8)
The Weekly (18)
Vaccines (189)
Venture capital (34)
Weight loss (25)
Women's health (6)
Date
Last 7 days (154)
Last 30 days (547)
Last 365 days (8356)
2026 (959)
2025 (8409)
2024 (9467)
2023 (10639)
2022 (13113)
2021 (13177)
2020 (10962)
2019 (8593)
2018 (6333)
2017 (7122)
2016 (6284)
2015 (6949)
2014 (4524)
2013 (3091)
2012 (3341)
2011 (3329)
2010 (3038)
Location
Africa (88)
Alabama (19)
Alaska (1)
Arizona (25)
Arkansas (2)
Asia (11409)
Australia (1541)
California (3142)
Canada (707)
China (598)
Colorado (82)
Connecticut (129)
Delaware (240)
Europe (20776)
Florida (411)
Georgia (12)
Idaho (6)
Illinois (308)
India (18)
Indiana (100)
Iowa (9)
Japan (208)
Kansas (10)
Kentucky (13)
Maine (4)
Maryland (336)
Massachusetts (2482)
Michigan (27)
Minnesota (111)
Missouri (12)
Montana (8)
Nebraska (2)
Nevada (10)
New Hampshire (13)
New Jersey (890)
New Mexico (3)
New York (745)
North Carolina (237)
Northern California (1664)
Ohio (66)
Oklahoma (1)
Oregon (5)
Pennsylvania (464)
Puerto Rico (3)
Rhode Island (6)
South America (117)
South Carolina (3)
Southern California (1238)
Tennessee (36)
Texas (540)
United States (10577)
Utah (75)
Virginia (26)
Washington D.C. (9)
Washington State (293)
Wisconsin (35)
131,345 Results for "cullinan oncology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lung cancer
Cullinan, Taiho’s NSCLC Hopeful Shows ‘Strong Activity,’ Clearing Road to FDA
Cullinan Therapeutics and Taiho Oncology’s zipalertinib elicited promising response rates in two mid-stage studies of non-small cell lung cancer patients with typical and uncommon EGFR mutations.
September 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 5, 2026
·
1 min read
Press Releases
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
January 8, 2026
·
9 min read
Autoimmune disease
Cullinan Bets $700M+ in Back-Heavy China Deal for Autoimmune T Cell Engager
Genrix’s velinotamig complements Cullinan’s own pipeline, according to William Blair, which added that the deal will put Cullinan in a better position to target autoimmune diseases.
June 5, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
October 13, 2025
·
9 min read
Press Releases
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
September 9, 2025
·
11 min read
Press Releases
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 6, 2025
·
10 min read
Press Releases
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
November 21, 2025
·
9 min read
Press Releases
Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
November 10, 2025
·
1 min read
Press Releases
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
July 23, 2025
·
8 min read
1 of 13,135
Next
